CARLSBAD, Calif., April 26, 2017 /PRNewswire/ -- Ionis
Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will
host a live webcast on Tuesday, May 9
at 11:30 a.m. Eastern Time to discuss
its first quarter 2017 financial results and report on pipeline and
business progress.
Interested parties may listen to the call by dialing
877-443-5662 or access the webcast at www.ionispharma.com. A
webcast replay will be available for a limited time at the same
address.
ABOUT IONIS PHARMACEUTICALS, INC.
Ionis is the leading
company in RNA-targeted drug discovery and development focused on
developing drugs for patients who have the highest unmet medical
needs, such as those patients with severe and rare diseases. Using
its proprietary antisense technology, Ionis has created a large
pipeline of first-in-class or best-in-class drugs, with over three
dozen drugs in development. SPINRAZA™ (nusinersen) is a drug that
has been approved in the U.S. for the treatment of spinal muscular
atrophy (SMA) in pediatric and adult patients. Biogen is
responsible for commercialization of SPINRAZA. Drugs currently in
Phase 3 development include volanesorsen, a drug Ionis is
developing and plans to commercialize through its wholly owned
subsidiary, Akcea Therapeutics, to treat patients with either
familial chylomicronemia syndrome or familial partial
lipodystrophy; and IONIS-TTRRx, a drug Ionis is
developing with GSK to treat patients with TTR amyloidosis. Ionis'
patents provide strong and extensive protection for its drugs and
technology. Additional information about Ionis is available at
www.ionispharma.com.
IONIS' FORWARD-LOOKING STATEMENT
This press release
includes forward-looking statements regarding Ionis
Pharmaceuticals' financial position and outlook, Ionis' business,
the business of Akcea Therapeutics, Inc., a subsidiary of Ionis
Pharmaceuticals, and the therapeutic and commercial potential of
Ionis' technologies and products in development, including
SPINRAZA, IONIS-TTRRx and volanesorsen. Any statement
describing Ionis' goals, expectations, financial or other
projections, intentions or beliefs is a forward-looking statement
and should be considered an at-risk statement. Such statements are
subject to certain risks and uncertainties, particularly those
inherent in the process of discovering, developing and
commercializing drugs that are safe and effective for use as human
therapeutics, and in the endeavor of building a business around
such drugs. Ionis' forward-looking statements also involve
assumptions that, if they never materialize or prove correct, could
cause its results to differ materially from those expressed or
implied by such forward-looking statements. Although Ionis'
forward-looking statements reflect the good faith judgment of its
management, these statements are based only on facts and factors
currently known by Ionis. As a result, you are cautioned not to
rely on these forward-looking statements. These and other risks
concerning Ionis' programs are described in additional detail in
Ionis' annual report on Form 10-K for the year ended December 31, 2016, which is on file with the SEC.
Copies of this and other documents are available from the
Company.
In this press release, unless the context requires otherwise,
"Ionis," "Company," "we," "our," and "us" refers to Ionis
Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals,
Inc. Akcea Therapeutics™ is a trademark of Ionis
Pharmaceuticals, Inc. SPINRAZA™ is a trademark of Biogen.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-to-hold-first-quarter-2017-financial-results-webcast-300445693.html
SOURCE Ionis Pharmaceuticals, Inc.